Human TorsinA can function in the yeast cytosol as a molecular chaperone

I lectra Adam*, Lyne Jossé† and Mick F. Tuite†
Kent Fungal Group, School of Biosciences, University of Kent, Canterbury, Kent CT2 7NJ, U.K.
Correspondence: Mick F. Tuite (m.f.tuite@kent.ac.uk)

TorsinA (TorA) is an AAA+ (ATPases associated with diverse cellular activities) ATPase linked to dystonia type 1 (DYT1), a neurological disorder that leads to uncontrollable muscular movements. Although DYT1 is linked to a 3 bp deletion in the C-terminus of TorA, the biological function of TorA remains to be established. Here, we use the yeast Saccharomyces cerevisiae as a tractable in vivo model to explore TorA function. We demonstrate that TorA can protect yeast cells against different forms of environmental stress and show that in the absence of the molecular disaggregase Hsp104, TorA can refold heat-denatured luciferase in vivo in an ATP-dependent manner. However, this activity requires TorA to be translocated to the cytoplasm from the endoplasmic reticulum in order to access and process cytoplasmic protein aggregates. Furthermore, mutational or chemical inactivation of the ATPase activity of TorA blocks this activity. We also find that TorA can inhibit the propagation of certain conformational variants of [PSI⁺], the aggregated prion form of the endogenous Sup35 protein. Finally, we show that while cellular localisation remains unchanged in the dystonia-linked TorA mutant ΔE302-303, the ability of this mutant form of TorA to protect against cellular stress and to facilitate protein refolding is impaired, consistent with it being a loss-of-function mutation.

Introduction

TorsinA (TorA) was originally identified as a protein connected with human dystonia type 1 (DYT1), a congenital movement disorder [1,2], and thus, its biological function has since attracted much interest. DYT1 is associated with a three-base pair (ΔGAG) deletion that removes one of a pair of glutamic acid residues (Glu-302/303) from near the C-terminus of TorA [3–5]. However, the apparent association of TorA with several different cellular compartments and cofactors and its implication in multiple cellular roles [6] continues to confuse researchers as efforts are made to understand how it contributes to this neurological disorder.

TorA is targeted to the lumen of endoplasmic reticulum (ER) by a 20 amino acid, N-terminal signal sequence [7–9], where it is glycosylated. In the ER, TorA is anchored to the ER membrane via a short hydrophobic domain that is exposed by cleavage of the signal sequence [3,10,11]. Two cysteine residues in this N-terminal hydrophobic domain act as a proteolytic cleavage site, and ER stress triggers this cleavage leading to the mobilisation of TorA from the ER membrane [12]. Some of the functions of TorA, however, have been linked to membrane attachment and assembly due to its interaction with the nuclear envelope protein LAP1 (lamina-associated polypeptide) and the ER membrane-associated LULL1 (luminal domain-like LAP1), two cofactors that also regulate TorA ATPase activity [4,13]. TorA is also associated with anterograde cytoplasmic transport via binding with the cytoplasmic kinesin light complex (KLC1) [14], while a recent study in Drosophila has implicated TorA in regulating cellular lipid metabolism [15]. All these studies suggest that the biological role(s) of TorA are defined to some extent by its relevant subcellular location.
TorA is a member of the superfamily of AAA+ (ATPases associated with diverse cellular activities) ATPases that are associated with diverse cellular activities [10,16], although TorA is the only member that is ER-associated. Several studies have suggested a role for TorA in protecting eukaryotic cells against protein misfolding, aggregation and proteotoxicity [17–21]. How this protective role is achieved remains to be established, but possibly relates to a chaperone-like activity. This possibility emerged from the realisation that TorA has a significant level of amino acid sequence identity with ClpB [3,16], a member of the AAA+ superfamily that acts as a molecular chaperone in bacteria. Subsequently, studies have shown that TorA can reaggregate heat-denatured luciferase in vitro [22], but as yet there has been no report of such protein disaggregase activity in vivo. Elevated levels of TorA can certainly protect cells against various forms of stress, such as heat shock and oxidative stress, consistent with a chaperone-like function in vivo [19–21]. That TorA co-localises with the Hsp70/40 chaperones in Lewy bodies to suppress α-synuclein aggregation suggests a putative interaction between TorA and the endogenous chaperone network to target misfolded proteins [17].

To explore the function and mechanism of action of TorA, we have used the yeast *Saccharomyces cerevisiae* as an in vivo test bed. *S. cerevisiae* is an attractive unicellular model in which to explore the fundamental aspects of cellular mechanisms and has been, for example, successfully employed in the study of certain proteopathies [23–25]. A previous study by Valastyan and Linquist [26] found that directing TorA to the ER of yeast was not detrimental to growth, but they were unable to demonstrate an impact on either protein folding or secretion albeit with a limited set of test substrates. A subsequent study demonstrated that TorA can be directed to the yeast ER using the native human TorA signal sequence, and using this system, the authors were able to demonstrate the essential role played by resident ER chaperones, specifically BiP, in TorA biogenesis [27].

*S. cerevisiae* does not encode an orthologue of TorA, but it does have many AAA+ ATPases including Hsp104, a mainly cytoplasmic protein that has been phylogenetically linked to the ClpB/Hsp100 family of molecular chaperones. Hsp104 has no close mammalian orthologue, but like other members of the AAA+ ATPase family it assembles into a homo-hexameric ring-like structure [28,29]. The major cellular role of Hsp104 is a protective one, ensuring the recovery from heat shock during which the protein’s disaggregase activity facilitates the reactivation of misfolded proteins. This function is coupled with ATP hydrolysis [30–34], itself driven by various regulatory co-chaperones. While TorA contains one nucleotide domain (NBD (nucleotide-binding domain)) with motifs that are important for ATP binding (Walker A) and hydrolysis (Walker B) [35,36], Hsp104 has two such domains, NBD1 and NBD2. A series of point mutations have been described in the NBDs that impair nucleotide-binding activity of both Hsp104 [37,38] and TorA [39,40]. The ATPase activity of Hsp104 can also be inhibited in vivo by growing cells in millimolar concentrations of the protein-denaturing agent guanidine hydrochloride (GdnHCl) [41–43], but any effect of GdnHCl on TorA has not been reported.

While TorA and Hsp104 differ in their main pattern of cellular localisation and the number of NBDs, they clearly share many structural and functional properties. For example, they both protect cells against different forms of stress — albeit in different contexts — so determining whether they can functionally substitute for each other in vivo would shed new light on the cellular role of TorA.

**Materials and methods**

**Plasmid construction**

Plasmid pUKC2752 was generated by cloning TorA cDNA as a BamHI–Sall fragment into the URA3-based expression plasmid pBEVY-U, which has the constitutive *ADH1* promoter [44]. Single residue TorA mutants were constructed with the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) using pUKC2752 as the template. Plasmid pUKC2753 was created using pUKC2752 as a template to amplify ΔN-TorA (TorsinA lacking the N-terminal signal sequence) as a BamHI–Sall fragment and to ligate into pBEVY-U. Versions of TorA and ΔN-TorA that were N-terminally tagged with GFP were created using Gateway Cloning Technology (Invitrogen) with the BP and LR recombination reactions being carried out essentially according to the manufacturer’s instructions. The resulting plasmids were designated pUKC2774 (TorA-GFP) and pUKC2776 (ΔN-TorA-GFP). The oligonucleotide primers used for mutagenesis are listed in Supplementary Table S1.

A plasmid based on pBEVY-U and expressing the wild-type *S. cerevisiae HSP104* gene (designated pUKC2751) was previously made in this laboratory. The plasmid pJK59 (also called pPS1622) encodes...
Sec63-GFP, a fusion of the S65T/V163A double mutant of GFP to the C-terminus of Sec63, under the SEC63 promoter, and was a gift from Pamela Silver (AddGene plasmid # 8854).

Yeast strains
The *S. cerevisiae* strains BY4741 (*MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0*), YJW532 Δhsp104 (*MATa ade1-14 his3-11,15 leu2-3,112 ura3-1 trp1-1 can1-100, hsp104::HIS3, pRS316HSP104*) and 74D-694 (*MATα ade1-14 trp1-289 his3Δ1-200 ura3-52 leu2-3,112*) were used in the present study. BY4741 was used for the luciferase and stress assays (see below) as well as the TorA localisation studies, while *[psi−]* and *[PSI+]* versions of 74D-694 strains and the YJW532 strain were used for the prion assays.

Galactose-induced gene expression
Typically, yeast cells transformed with *URA3*-based plasmids pUKC2762 or the backbone plasmid pYES2 were grown overnight at 30°C in a yeast nitrogen base (YNB)-based pre-induction synthetic complete medium (0.67% YNB, supplemented with amino acid plus base mix without uracil, Formedium) with 2% raffinose. Cells were then harvested and transferred to induction medium (the same synthetic complete medium lacking uracil but with 2% galactose rather than raffinose) and incubated for a further 16–18 h before being collected for protein extraction.

Western blot analysis
Cell-free extracts were prepared from logarithmic phase cultures as described by von der Haar [45] and were analysed by SDS–PAGE using either NuPAGE 10% Bis–Tris gels or 4–20% Tris–Glycine gradient gels (Invitrogen). Proteins were then transferred onto the PVDF membrane (Roche) and probed with either an anti-TorA polyclonal antibody (gift from Dr Lisa Swanton, University of Manchester), or an anti-Hsp104 polyclonal antibody (from our own laboratory), or an anti-Sup35 polyclonal antibody (MT50 from our laboratory) or an anti-phosphoglycerate kinase (PGK) polyclonal antibody (MT102 from our laboratory). Anti-rabbit HRP-conjugated antibodies (Sigma) were used as a secondary antibody in the ECL analysis. EndoH (New England Biolabs) digests were performed according to the manufacturer’s instructions prior to electrophoresis.

*In vivo* luciferase refolding assay
The *in vivo* luciferase refolding assay [46] was adapted from Zenthon et al. [47] and used the pGPDLuxAB (*HIS3*) plasmid which encodes a heat-sensitive Vibrio harveyi luciferase (gift from Susan Lindquist, Whitehead Institute for Biomedical Research, MIT). A single fresh colony of the relevant strain transformed with pGPDLuxAB(*HIS3*) was grown overnight in 5 ml of selective medium (0.67% YNB and 2% glucose supplemented with amino acid mixture without histidine, Formedium). Cells were then diluted to *A*$_{600}$ = 0.2 and grown on at 30°C to an *A*$_{600}$ = 0.4. At this point, the endogenous luciferase activity was measured using a BMG Labtech FLUOstar OPTIMA plate reader using 300 μl of cell suspension per reading. Decanal (5 μl, Sigma–Aldrich) was added to each cell sample giving a final concentration of ~90 mM. Luminescence was immediately read to give the 100% luciferase activity value. The rest of the culture was transferred to 46°C for 12 min, then cycloheximide was added to a final concentration of 10 μg/ml and the cultures were incubated at 46°C for a further 12 min at which point luciferase activity in 300 μl of cells was measured as before. The cells were then returned to 30°C to recover, and luciferase activity was measured in 300 μl samples every 30 min for periods up to 4 h. The percentage of refolded luciferase was calculated based on the 100% luciferase activity value. Three independent samples were taken for each time point for each strain/condition and the averages were calculated.

Cell stress assays
Cell stress assays were performed starting with cells in logarithmic phase (absorbance *A*$_{600}$ ~0.2) and growth was quantified by measuring the resulting absorbance at *A*$_{600}$ for 18–22 h using a BMG Labtech FLUOstar OPTIMA plate reader. For heat shock, cells were first pre-incubated at 37°C for 1 h followed by 2 h heat shock at 47°C. In some experiments, 3 mM GdnHCl was added prior to the shift to 47°C. For ethanol stress, a final concentration of 15% (v/v) ethanol was added to the cultures and growth was monitored for 22 h.
Cell imaging
Plasmids expressing green fluorescent protein (GFP) fusions with Sec63, Hsp104 and TorA and their respective mutants were individually transformed into both the BY4741 strain and a Δhsp104 derivative of this strain. Protein localisation assays were performed in logarithmic phase cells (A_{600} ∼0.4–0.6) and visualised using the GFP excitation filter on an Olympus 1×81 fluorescent microscope with a Hamamatsu Photonics Orca AG cooled CCD camera. The resulting images were then processed using the CellR software (Olympus).

To study the impact of tunicamycin on localisation of GFP-tagged TorA in yeast, early logarithmic phase cells (A_{600} ∼0.4–0.6) were first exposed to tunicamycin (10 μg/ml final concentration; Sigma, dissolved in DMSO) for 2 h at 30°C with shaking at 200 rpm. The cells were then visualised using a fluorescent microscope as described above. Tunicamycin treatment was also studied in pre-heat-shocked cells at 37°C for 1 h prior to the addition of tunicamycin.

Plasmid shuffling and phenotyping analysis
Plasmid pAG425GPD-ccdB-TorA-EGFP-LEU2 expressing a TorA-GFP fusion (generated by Susan Lindquist’s Laboratory, obtained from Addgene #14202) was introduced into a derivative YJW532 strain that carries an hsp104::kanMX disruption and a single-copy URA3-based plasmid pRS316 [48] expressing the HSP104 gene and designated pRS318-URA3-HSP104. This strain, a gift from Lev Osherovich and Jonathan Weissman (UCSF), and both plasmids were selected for on -leu- and -ura YNB-based synthetic medium as appropriate. Ura− cells lacking the pRS316-URA3-HSP104 plasmid were selected for by growing the double transformants overnight at 30°C in synthetic -leu/-ura medium followed by plating on YEPE supplemented with 5-fluoroorotic acid (5-FOA; 1 mg/ml). The resulting Leu+ Ura− cells had lost the pRS316-URA3-HSP104 plasmid. Further selection on -leu medium was used to identify strains that retained the pAG425GPD-ccdB-EGFP-LEU2 plasmid. The desired Leu+ Ura− colonies were streaked on 1/4 YEPE with and without 3 mM GnHCl and incubated for 2 days. The [PSI+] -associated phenotype was scored based on suppression or not of the ade1-14 mutation; [PSI−] cells give rise to white colonies while [psi−] cells give rise to red Ade− colonies.

Statistical analysis
Two-way ANOVA was used for statistical analysis, using Minitab software, with the threshold for statistical significance difference taken at a 95% confidence interval. Tukey’s HSD post hoc test was used to determine significant differences.

Results
The native signal sequence of TorA targets the protein to the yeast ER
To study the cellular function of TorA, we first needed to be able to direct it to different subcellular compartments in yeast. Two plasmids were constructed, pUKC2752 constitutively expressing the full-length wild-type TorA with its 20 residue N-terminal signal sequence for ER localisation, and a second, pUKC2753 constitutively expressing a truncated form of TorA lacking the signal sequence (designated ΔN-TorA). Both forms were expressed as confirmed by western blotting with the reduced molecular mass of ΔN-TorA consistent with a non-ER-associated and hence non-glycosylated form of TorA (Figure 1A). An endogenous protein of the same approximate molecular mass as TorA was also observed, but its identity remains to be established.

To confirm their respective localisation, GFP was fused to the C-terminus of TorA and ΔN-TorA proteins to generate plasmids pUKC2774 and pUKC2776, and the localisation of the fusion proteins was assessed by fluorescence microscopy and comparing to Sec63, an ER membrane-associated protein. The expressed TorA-GFP showed a localisation pattern in 87% of the 200 cells examined that was consistent with its localisation to the ER, i.e. it mirrored the observed Sec63-GFP localisation pattern (Figure 1B). The remaining 17% of cells showed an apparent cytoplasmic localisation for TorA-GFP. There was no evidence of nuclear localisation. As expected, no ΔN-TorA-GFP was detected in the ER, but predominantly in the cytoplasm (56% of the 200 cells examined) and the remainder as foci associated with the cell membrane.

If TorA was localised to the ER as the GFP studies suggest, we would expect the protein to be glycosylated as the protein has two Asn-linked glycosylation sites at residues 143 and 158. To confirm that the expressed TorA was N-linked glycosylated, the TorA and the ΔN-TorA-expressing cells were grown in the presence of tunicamycin, an inhibitor of N-linked glycosylation in yeast [49]. In the tunicamycin-treated cells, TorA-GFP was
now evident as cytoplasmic inclusions (Figure 1C). This behaviour could be explained either as a result of misfolded non-glycosylated TorA being returned to the cytoplasm by the ERAD pathway or by failure of TorA to translocate into the ER as a consequence of induction of the unfolded protein response [50]. Tunicamycin had no impact on the localisation or cytoplasmic form of ΔN-TorA consistent with it not entering the ER, while Sec63 remained ER membrane-associated. The nature of the TorA glycoforms was confirmed using digestion with EndoH, an enzyme that cleaves asparagine-linked mannose-rich oligosaccharides from glycoproteins [51], and this resulted in a reduced molecular mass for TorA consistent with full de-glycosylation (Figure 1D).

Figure 1. Localisation and post-translational modification of human TorA expressed in S. cerevisiae. 
(A) Western blot analysis using an anti-TorA antibody of total protein extracts from cells expressing either full-length TorA (TorA) or a version lacking the N-terminal signal sequence (ΔN-TorA). The control shown is cells carrying the plasmid pBEVY-U (control). Synthesis in the BY4741 parent strain (HSP104*) or BY4741 carrying a deletion of the HSP104 gene (Δhsp104) are shown. PGK was used as the protein loading control. (B) Localisation of TorA-GFP and ΔN-TorA-GFP fusion proteins in yeast compared with a Sec63-GFP fusion protein. The white arrows indicate localisation in the ER, and the figures are the percentage of cells (n = 200) showing localisation to either the ER or the cytoplasm. The magnification used was ×60. NB: 44% of the ΔN-TorA-GFP-expressing cells showed predominantly cell membrane-associated foci (not shown). (C) Localisation of TorA-GFP and ΔN-TorA-GFP in cells grown in the presence (+Tun) or absence (−Tun) of tunicamycin (10 μg/ml) at 30°C. The magnification used was ×60 and the size bar is 2 μm. (D) Western blot analysis of TorA in protein extracts prepared from a wild type (HSP104*) and Δhsp104 strains expressing TorA. Cells were either treated with EndoH (+EndoH) or not (−EndoH). The glycosylated form (+G) and non-glycosylated form (−G) of TorA are indicated.

TorA protects yeast cells against environmental stress in an ATPase-dependent manner

The cytoplasmically located AAA+ ATPase, Hsp104, that shows sequence homology to TorA has a key role in tolerance to various forms of environmental stress in yeast [31]. To explore whether TorA was able to functionally replace Hsp104 to protect cells against such environmental stress, we examined the response of the strain...
BY4741 carrying a Δhsp104 deletion to heat stress. A previous study reported that expression of TorA in wild-type (HSP104) yeast had no effect on how the cells responded to a mild heat stress (39°C) [27]. Consequently, we conducted experiments in absence of Hsp104 that is essential for the acquisition of thermotolerance in yeast [30] and at higher temperatures. Expressing TorA or ΔN-TorA in the Δhsp104 mutant did not negatively effect on levels of expression of the mature TorA protein, although the levels of ΔN-TorA were slightly reduced in the Δhsp104 mutant (Figure 1A).

TorA, ΔN-TorA or wild-type Hsp104 was expressed in the Δhsp104 strain and compared with the vector alone as the control, under the following assay conditions. Cells were pre-incubated at 37°C for 1 h and then subjected to a 2 h heat shock at 47°C. After returning the heat-shocked cells to 30°C, absorbance was monitored at A600 continuously for a further 18 h. The Δhsp104 cells showed no growth even after 18 h, whereas the same strain expressing wild-type Hsp104 recovered after a lag phase of ~6 h albeit with a slightly reduced doubling time (Figure 2A). Expression of TorA in the same Δhsp104 mutant restored growth post heat shock to a similar extent to the Hsp104 control with a 6 h lag phase and a slightly reduced doubling time (Figure 2B). For the ΔN-TorA-expressing cells, there was a longer lag phase (~10 h), but the resulting doubling time was again only slightly lower than the control (Figure 2B). These data show that TorA can functionally replace Hsp104 in protecting cells against heat stress.

Hsp104-mediated thermotolerance in yeast relies on ATP binding and hydrolysis, and the hydrolysis step can be inhibited in vivo by 3 mM GdnHCl [43,52]. As TorA also binds and hydrolyses ATP [3], we next determined whether a similar concentration of GdnHCl also inhibited the ability of TorA to functionally replace Hsp104 in the thermotolerance assay. The addition of 3 mM GdnHCl to the Hsp104-expressing cells when they were returned to 30°C cells post heat shock increased the lag phase and reduced the rate of growth (Figure 2A). The ability of TorA to rescue the growth of the Δhsp104 cells following heat stress was also inhibited by 3 mM GdnHCl with the lag phase increased to 12 h and a reduced rate of growth (Figure 2B). A similar but less marked trend was also seen for the ΔN-TorA-expressing cells in the presence of 3 mM GdnHCl. These findings are consistent with low millimolar levels of GdnHCl-inhibiting TorA function in vivo. While it is conceivable that GdnHCl may have secondary effects on other ATPases required for protein refolding that are only evident in cells lacking Hsp104, we have previously shown that the loss of acquired thermotolerance in a Δhsp104 is not further reduced by 3 mM GdnHCl [41].

Given that TorA was localised to the ER while ΔN-TorA was largely in the cytoplasm, the observation that both forms were able to complement the thermotolerance defect was surprising. However, in rat cells, TorA can translocate from the ER to the cytoplasm following an ER stress [8]. We therefore examined whether the 47°C heat stress applied here resulted in translocation of TorA from the yeast ER to the cytoplasm. Remarkably, TorA-GFP was found to completely re-localise to the cytoplasm after 2 h at 47°C, marking that are only evident in cells lacking Hsp104, we have previously shown that the loss of acquired thermotolerance in a Δhsp104 mutant did not negatively effect on levels of expression of the mature TorA protein, although the levels of ΔN-TorA were slightly reduced in the Δhsp104 mutant (Figure 1A).

The ability of Hsp104 to protect cells against thermal and ethanol stress is directly related to its function as a molecular chaperone, breaking down protein aggregates arising as a consequence of stress-induced protein misfolding. Previous studies have shown that TorA, like Hsp104, can recognise and refold heat-denatured (i.e. misfolded) luciferase in vitro, in keeping with a molecular chaperone function [22]. To establish whether such chaperone activity could be detected in vivo, we exploited a V. harveyi luciferase-based assay used to demonstrate the chaperone function of Hsp104 from different yeast strains [46,47]. This in vivo protein refolding assay uses a heat-denatured V. harveyi luciferase fusion protein as a substrate. The basal luciferase activity is measured at 30°C representing the correctly folded luciferase prior to a short 46°C heat shock. The reactivation of the heat-denatured luciferase is then monitored over 4 h at 30°C in the presence of cycloheximide.

Δhsp104 strains expressing either TorA or ΔN-TorA were co-transformed with the plasmid pGDP-LuxAB expressing V. harveyi luciferase. In the Δhsp104 strain after the cells were returned to 30°C post heat shock, there
was as expected minimal recovery of the luciferase activity, and even after 4 h, the levels only reached 15% of the pre-heat stress levels. In contrast, after 4 h, cells expressing Hsp104 showed almost 90% of the starting levels of functional luciferase (Figure 3A). Expression of TorA was also able to reactivate luciferase to significantly higher levels than observed in the control (\( t = 240 \text{ min}; P < 0.05 \)), although there was an increased lag before maximal reactivation of luciferase was observed (Figure 3A). Such in vivo reactivation of a thermally denatured enzyme in the absence of Hsp104 is consistent with TorA having the ability to function as a molecular chaperone in vivo.

To establish whether or not the chaperone activity of TorA required ATP hydrolysis, the luciferase refolding experiment was repeated in the presence of 3 mM GdnHCl (Figure 3B). The ability of both Hsp104 and TorA to reactivate the luciferase in the presence of 3 mM GdnHCl was significantly reduced (\( t = 210 \text{ min}; P < 0.05 \)), consistent with TorA requiring ATP hydrolysis to mediate refolding of the luciferase in vivo. These results further support the hypothesis that TorA has the properties of an ATP-dependent chaperone in vivo.

**Walker motif mutations in TorA affect on its chaperone activity in vivo**

TorA has a single NBD with a non-canonical Walker A motif (GxxxxGKN) and a canonical Walker B motif (hhhhDE). The Walker motifs play an essential role in the function of other AAA+ ATPases including Hsp104 \([29,53]\). To further explore the role of TorA in vivo, we therefore generated several different mutations in these motifs and determined how these affected on the function and localisation of TorA expressed in yeast.

Single mutations were introduced into the Walker A motif (TorA\(^{K108T} \)) unable to bind ATP) and B motif (TorA\(^{E171Q} \), can bind but not hydrolyse ATP) and expressed in yeast. Although the TorA\(^{K108T} \) mutant was expressed at a lower steady-state level than the wild-type TorA, this was not so for TorA\(^{E171Q} \) mutant.

---

**Figure 2. TorA can functionally replace Hsp104 in providing protection against thermal and chemical (ethanol) stress.**

**A** Thermal stress assay. Shown are growth profiles of a Δhsp104 strain continuously measuring culture density at 30°C over a period of 18 h. Cells either contained the plasmid pBEVY-U (Vector) or plasmid pUKC2751 constitutively expressing the HSP104 gene under the control of the ADH1 promoter (Hsp104). HS (heat shock), growth after exposure to 37°C for 1 h followed by 2 h at 47°C. HS + GH, as for HS except guanidine hydrochloride (GH) was added to 3 mM before the shift to 47°C.

**B** As for (A) except the Δhsp104 strain was transformed with a plasmid expressing either TorA or ΔN-TorA as indicated.

**C** The effect of heat stress on the localisation of Hsp104-GFP, TorA-GFP and ΔN-TorA-GFP fusion proteins in yeast compared with a Sec63-GFP fusion protein. The figures are the percentage of cells (\( n = 200 \)) with the localisation pattern shown. The magnification used was ×60 and the size bar is 2 μm.

**D** Growth of the Δhsp104 strain in the presence or absence of 15% (v/v) ethanol. The strain was either transformed with pBEVY-U (vector) or plasmids constitutively expressing Hsp104, TorA or ΔN-TorA. Growth was monitored as in (A) and (B).

© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Zacchi et al. [27] have previously reported that the TorAK108T, but not the TorAE171Q, mutation leads to an increased rate of degradation of TorA. Neither mutation had an effect on TorA localisation with both mutant proteins, when fused to GFP, being largely detected in the ER at 30°C (Figure 4B). Likewise, when subject to 47°C heat shock, the mutant proteins like the wild-type TorA protein re-localised to the cytoplasm (Figure 4B). When expressed in a Δhsp104 mutant, both TorA mutants showed a significantly reduced ability to refold heat-denatured luciferase compared with the wild-type TorA control (t = 210 min; P ≤ 0.05), although the measurable refolding activity was not completely eliminated (Figure 4C). These data further support the hypothesis that TorA acts as an ATP-dependent chaperone in vivo.

Nagy et al. [54] reported that mutating the canonical Walker A motif into a non-canonical one reduced the activity of ClpB, the bacterial orthologue of Hsp104, both with respect to acquired thermotolerance and protein refolding. To explore whether restoring the canonical Walker A motif in TorA would positively affect on its chaperone activity in vivo, we introduced the necessary mutation (i.e. N109T; giving GxxxxGK/T) and examined the activity of the TorAN109T mutant in vivo. The TorAN109T mutant did not affect the ability of TorA to refold luciferase (Supplementary Figure S1), and this may reflect an underlying mechanistic difference between TorA and ClpB in their function as chaperones.

Analysis of the in vivo function of the ΔE302 mutant of TorA
The role of the C-terminal domain of TorA has been studied primarily in relation to a single glutamic acid deletion (positions 302–303; designated TorAΔE302) that is associated with the disease torsion dystonia [3,16]. Despite a plethora of in vitro and in vivo studies in Drosophila, mammalian cells and in yeast, it is still unclear whether or not this mutation causes loss of function of TorA [17,21,55] or mislocalisation [7,14,27,56–61]. Under normal growth conditions, i.e. 30°C, we found that TorAΔE302, although expressed at a lower steady-state level than the wild-type TorA, was still targeted to the yeast ER and capable of translocating to the cytoplasm.
following a thermal stress (Figure 4B). However, expression of TorAΔE302 in the Δhsp104 mutant resulted in a significant reduction in the ability to refold heat-denatured luciferase compared with wild-type TorA \((t=210\,\text{min}; \quad P \leq 0.05)\) and with a level seen with the two ATPase mutants of TorA analysed (Figure 4C). This finding suggests a loss of chaperone function of TorAΔE302 in our yeast in vivo model.

**TorA can eliminate specific prion conformers from yeast cells**

In the functional studies described above, we examined the role of TorA in dealing with protein aggregates generated by thermal stress in vivo. Such protein aggregates are generally amorphous in nature, and because Burdette et al. [22] had shown that that TorA may only deal with a particular subtype of protein aggregate, we also investigated whether TorA was able to process the highly ordered amyloid aggregates generated by the yeast protein Sup35 that give rise to the cytoplasmically transmitted [PSI+] prion.

There are several different conformational variants of the [PSI+] prion that affect to different extents on the non-sense suppression phenotype associated with the presence of the prion. ‘Weak’ [PSI+] variants have unstable phenotypes, low levels of non-sense suppression, and show mitotic instability and higher molecular mass, detergent-resistant Sup35 aggregates. In contrast, ‘strong’ [PSI+] variants contain predominantly aggregated Sup35 and are phenotypically characterised by high levels of non-sense suppression [62]. These phenotypic differences reflect an underlying difference in amyloid conformation [63].

Overexpression of Hsp104 eliminates the [PSI+] prion from cells [64], and so we investigated whether expression of TorA similarly affected the maintenance of the [PSI+] prion. As Hsp104 targets prion aggregates in the
cytoplasm, we examined the localisation of TorA in both [PSI⁺] variants and found it to be predominantly localised to the cytoplasm in this strain (Supplementary Figure S2). This difference could reflect the fact that the 74D-694 strain is genetically distinct to the BY4741 strain used in our other studies. In a strong [PSI⁺] variant of the yeast strain 79D-694, no effect on the prion was observed, whereas in the weak [PSI⁺] variant examined, [PSI⁺] was eliminated by expression of TorA (Figure 5A). When the weak [PSI⁺] cells expressing TorA were plated onto YEPD, ~30% of the transformed cells formed red [psi⁻] colonies (Figure 5B). Expression of truncated AN-TorA did not affect [PSI⁺] maintenance in either [PSI⁺] variant, suggesting that the ER targeting and glycosylation state are essential for [PSI⁺] elimination mediated by TorA. Similarly, expression of the ΔE302 mutant of TorA did not affect the maintenance of either [PSI⁺] variants consistent with it being a loss-of-function mutant (data not shown). Thus, TorA expressed in yeast eliminates the [PSI⁺] prion in a prion variant-specific manner, suggesting that TorA may only recognise particular amyloid conformations of Sup35.

The maintenance of the [PSI⁺] prion during cell division also depends on normal levels of Hsp104 [64], because the chaperone is required to fragment the Sup35 amyloid form to generate transmissible forms of Sup35, i.e. [PSI⁻] propagons. These are forms of the prion aggregate that can be passed on to daughter cells and hence propagate the prion state. We therefore determined whether TorA can functionally replace the prion maintenance function of Hsp104 in vivo. This was achieved using the strong [PSI⁺] strain YJW532, which carries a deletion of the HSP104 gene, but also expresses wild-type Hsp104 from a centromeric plasmid with a URA3 marker. A TorA-expressing plasmid pAG425GPD-ccdB-TorA-EGFP-LEU2 was transformed into the YJW532 strain, and the resulting transformants were plated onto 5-FOA plates to select for Ura⁻ cells that had lost the Hsp104-expressing plasmid pRS316 [48]. Resulting Ura⁻ transformants were analysed for the [PSI⁺] phenotype of the YJW532 by plating onto 1/4 YEPD. None of the independent transformants examined showed a [PSI⁺] phenotype, demonstrating that TorA cannot maintain [PSI⁺] in the absence of Hsp104 (Figure 5C).

Discussion

TorA is a member of the AAA⁺ ATPase superfamily of proteins, members of which share many structural properties, but which participate in a wide range of cellular functions [53]. Besides containing the motifs that define ATP binding and hydrolysis (i.e. Walker A and B and Sensor I and II motifs), TorA and other members of the family contain several other conserved domains. TorA is, however, considered an atypical member of the AAA⁺ ATPase family of proteins [6] for three reasons: (i) it has a non-canonical Walker A motif although as we show here (Supplementary Figure S1) this has no impact on its chaperone function per se; (ii) it lacks an arginine finger, the highly conserved catalytic arginine residue that is integral to the formation of the ATP-binding pocket [65] and (iii) it is the only AAA⁺ ATPase that resides in the ER. Yet, even though TorA was first described 20 years ago [3], there still remains considerable debate as to the normal cellular role(s) played by this glycoprotein in its various subcellular locations (see [6,66] for recent reviews).

Predominant among the AAA⁺ ATPase superfamily are molecular chaperone proteins that can remodel protein conformation or more complex protein structures. Molecular chaperones play an important role in maintaining protein homeostasis (for recent reviews, see [67]) by ensuring that misfolded proteins are removed before they can negatively affect on cellular functions and, consequently, cell viability. Failure of the molecular chaperone network and the resulting breakdown in protein homeostasis can have widespread ramifications including the emergence of neurological and neurodegenerative diseases [68,69]. The TorA-linked dystonia DYT1 is one such neurological disorder, yet how the functional impairment of TorA leads to the characteristic involuntary muscle movements and ultimately paralysis is poorly understood or indeed whether this is a result of a breakdown in protein homeostasis.

Given its sequence relationship to two members of the AAA⁺ ATPase family that have well-defined roles as molecular chaperones, i.e. Hsp104 and ClpB, it is plausible that a defect in TorA activity results in a breakdown of neuronal proteostasis. By exploring the chaperone-related activities of mammalian TorA in S. cerevisiae, we have tested this hypothesis. As demonstrated by two previous studies using yeast to explore different aspects of human TorA function [26,27], this highly tractable organism offers many advantages for both exploring TorA function, but also as a research platform for the wider study of protein homeostasis, chaperone function and the role of chaperones in certain proteinopathies [70,71].

Various lines of evidence have pointed to TorA acting as a chaperone that can participate in protein quality control specifically in relation to protein assembly in the ER [61,72]. These lines of evidence are either indirect...
or come from in vitro studies [e.g. 22]. Our study provides the first direct evidence that human TorA can function as an ATP-dependent molecular chaperone in vivo. We have done so by demonstrating that TorA can mediate the refolding of heat-denatured luciferase (Figure 3) and can rescue cells from stress-induced damage (Figure 2B,D). In both experiments, we used yeast cells lacking the ATP-driven disaggregase Hsp104 that is required for both activities in yeast, and thus, TorA appears to be able to functionally replace Hsp104 in this context.

That TorA can function in restoring protein function may seem surprising given that we have conformed the findings of Zacchi et al. [27] that native TorA is localised to the yeast ER (Figure 1B) while Hsp104 is either in the cytoplasm or in the nucleus [73]. This conundrum is resolved by our finding that TorA re-localises to the cytoplasm following the heat stress applied during these assays, where it presumably is able to work on cytoplasmic, misfolded substrates. Such re-localisation has been reported for TorA in mammalian cells subject to ER stress [8], and a previous study in which TorA with its native signal sequence was expressed at high levels in mammalian cells revealed the localisation of TorA to the nucleus [73]. This localisation data and that of Zacchi et al. [27], with the findings reported by Valastyan and Lindquist [26].

Mutating either the Walker A or Walker B motifs in the single NBD of TorA significantly impaired the ability of TorA to reactivate heat-denatured luciferase, but did not completely ablate this activity (Figure 4C). Previous studies have shown that mutating the Walker A motif in NBD2 of Hsp104, while leading to a defect in ATP binding, nevertheless did not completely abolish the ability to reactivate heat-denatured GFP, while an equivalent mutation in NBD1 did ablate this activity [74]. This suggests a complex interplay between ATP binding, hydrolysis and protein remodelling by members of the AAA+ ATPase family and, as described above, TorA is considered to be an atypical member of this family and it is conceivable that it may act as a chaperone via a subtly different mechanism to that described for the archetypal members Hsp104 and ClpB [6].

That low millimolar concentrations of GdnHCl also impaired TorA function in vivo provides further evidence of the importance of TorA-mediated ATPase activity in reactivation of denatured luciferase (Figure 3B) and acquired thermostolerance (Figure 2B). GdnHCl directly inhibits the ATPase activity of Hsp104 without concomitant protein denaturation [43,52], but GdnHCl does not appear to act as a generic ATPase inhibitor. There have been reports that low millimolar levels of GdnHCl inhibit replication of both animal and plant positive-sense viruses [75] and, in poliovirus, this is a consequence of blocking ATP hydrolysis mediated by...
Our recent studies have suggested an alternative mechanism, namely that prion loss arises because of malpartition of the cell. Laudermilch and Schlieker [66] have recently suggested that TorA may act as a chaperone with the latter being associated with the ER membrane [87-89]. Both LAP1 and LULL1 are potent activators of TorA-mediated ATP hydrolysis, yet S. cerevisiae has no orthologues of either cofactor. Nevertheless, that our data show that the chaperone properties of TorA require ATP hydrolysis suggests that one of many co-chaperones that activate the ATPase activity of other chaperones, e.g. Sti1 that activates the ATP hydrolysis activity of Hsp70 [90], may provide this function. There have been no reports, to date, of co-expression of either LAP1 or LULL1 with TorA in yeast although the expression of another TorA protein, called printor, had no measurable impact on TorA function in yeast and mammalian cells.

For Hsp104 and its bacterial orthologue, ClpB to function effectively as a disaggregate requires co-operation with the endogenous chaperone network. In particular, many studies have shown that Hsp70 (Ssa 1 in yeast) and Hsp40 (Sis1 in yeast) mediate substrate binding of Hsp104 and the subsequent activation of the chaperone function upon binding to protein aggregates [77-80]. For TorA to function as a disaggregate, one would therefore expect that it would need to functionally co-operate with the endogenous Sis1/Ssa1 chaperones, yet the interactions between Hsp70 and ClpB/Hsp104 are known to show a degree of species specificity [81-82]. This species specificity is mediated by the interaction of Hsp70 with the central coiled-coil-forming M region of ClpB/Hsp104 [83,84], a region absent from TorA. However, there have also been reports that Hsp104 can disaggregate proteins via an ATP-independent mechanism, for example, in its role in propagating the prion form of Sup35 in yeast [35]. It therefore remains to be seen whether the chaperone function of TorA we detect in yeast is Hsp70-dependent or -independent although TorA co-localises with Hsp70 to misfolded forms of α-synuclein in Lewy bodies [17]. It also remains to be established whether or not the chaperone activity we observe is similar to that reported for ClpB/Hsp104 [79]. What does emerge from our studies is that TorA can, in part, replace the function of Hsp104 in rescuing yeast cells from physical or chemical stress most likely as a consequence of its chaperone-associated properties.

One cellular role of Hsp104 that could not be replaced by TorA was to maintain the [PSI+] prion in dividing cells (Figure 5C), despite its cytoplasmic localisation (Supplementary Figure S2). Hsp104 is essential for the propagation of [PSI+] and all other yeast prions through its ability to fragment the amyloid polymers into smaller transmissible forms of the prion aggregates, i.e. transmissible propagons. Yet intriguingly, overexpression of Hsp104 also eliminates the [PSI+] prion — but no other prions — from growing yeast cells [64]. This effect was originally believed to be a consequence of the increased fragmentation activity of the chaperone, but our recent studies have suggested an alternative mechanism, namely that prion loss arises because of malpartition of the [PSI+] propagons between mother and daughter cells in cells with elevated levels of Hsp104 leading to increased retention of the propagons by the mother cell [85]. This could be related to a non-productive interaction between Hsp104 and the M region of Sup35 [77,86]. Whether TorA is able to directly interact with Sup35 in the cytoplasm (Supplementary Figure S2) via this site remains to be established although Frederick et al. [86] show that the dynamics of the interactions between chaperones and the Sup35 amyloid form very much depends on the structure of the amyloid core. It is therefore perhaps significant that we have found that TorA expression only affects weak [PSI+] variants, which have a structure that is more robust and resistant to fragmentation by Hsp104, although it remains to be established whether loss of the weak variant of [PSI+] from the TorA-expressing cells is due to increased retention of the Sup35 aggregates by the mother cells or via other mechanism. Laudermilch and Schlieker [66] have recently suggested that TorA may act as a ‘holder chaperone’ and controls the tempo-spatial localisation of TorA and its associated factors.

Our data suggest that TorA has an ATP-driven function in vivo in yeast, yet there are several reports that TorA is inactive as an ATPase unless one of two cofactors are present. These cofactors are LAP1 and LULL1, with the latter being associated with the ER membrane [87-89]. Both LAP1 and LULL1 are potent activators of TorA-mediated ATP hydrolysis, yet S. cerevisiae has no orthologues of either cofactor. Nevertheless, that our data show that the chaperone properties of TorA require ATP hydrolysis suggests that one of many co-chaperones that activate the ATPase activity of other chaperones, e.g. Sti1 that activates the ATP hydrolysis activity of Hsp70 [90], may provide this function. There have been no reports, to date, of co-expression of either LAP1 or LULL1 with TorA in yeast although the expression of another TorA protein, called printor, had no measurable impact on TorA function in yeast [26]. Thus, the yeast TorA expression system we have established will allow us to further explore how the ATPase activity of TorA may be regulated and, by so doing, provide insights into a major human neurological disorder.

**Abbreviations**

5-FOA, 5-fluoroorotic acid; AAA+, ATPase associated with diverse cellular activities; BiP, binding immunoglobin protein; ClpB, caseinolytic peptidase B; DYT1, dystonia type 1; ER, endoplasmic reticulum; ERAD, endoplasmic reticulum associated protein degradation; GdnHCl, guanidine hydrochloride; GFP, green fluorescent protein; Hsp104, heat shock protein 104; LAP1, lamina-associated polypeptide; LULL1, luminal domain-like LAP1; NBD,
nucleotide-binding domain; PGK, phosphoglycerate kinase; TorA, TorsinA; YNB, yeast nitrogen base; ΔN-TorA, TorsinA lacking the N-terminal signal sequence.

Author Contribution
I.A. and L.J. carried out the experiments, M.F.T. and I.A. designed the experiments and all three authors contributed to interpretation of the results and the writing of the paper.

Funding
This work was supported by a Biotechnology and Biological Sciences Research Council PhD studentship awarded to I.A. and by the Biotechnology and Biological Sciences Research Council projects BB/H012982/1 and BB/E005969/1.

Acknowledgements
We would like to thank Dr Lisa Swanton (University of Manchester) for the human TorsinA cDNA and the anti-TorsinA antibody.

Competing Interests
The Authors declare that there are no competing interests associated with the manuscript.

References
1 Ozelius, L., Kramer, P.L., Moskowtiz, C.B., Kwiatkowski, D.J., Brin, M.F., Bressman, S.B. et al. (1989) Human gene for torsion dystonia located on chromosome 9q32-q34. *Neuron* 2, 1427–1434 doi:10.1016/0896-6273(89)90188-8
2 Risch, N.J., Bressman, S.B., deLeon, D., Brin, M.F., Burke, R.E., Greene, P.E. et al. (1990) Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. *Am. J. Hum. Genet.* 46, 535–538 PMC:1683634
3 Ozelius, L.J., Hewett, J.W., Page, C.E., Bressman, S.B., Kramer, P.L., Shalish, C. et al. (1997) The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. *Nat. Genet.* 17, 40–48 doi:10.1038/ng0997-40
4 Goodchild, R.E. and Dauer, W.T. (2005) The AAA+ protein torsinA interacts with a conserved domain present in LAP1 and a novel ER protein. *J. Cell Biol.* 168, 855–862 doi:10.1083/jcb.200411026
5 Breakfield, X.O., Blood, A.J., Li, Y., Hallett, M., Hanson, P.I. and Standaert, D.G. (2008) The pathophysiological basis of dystonias. *Nat. Rev. Neurosci.* 9, 222–234 doi:10.1038/nrn2337
6 Rose, A.E., Brown, R.S.H. and Schlieker, C. (2015) Torsins: not your typical AAA+ ATPases. *Crit. Rev. Biochem. Mol. Biol.* 50, 532–549 doi:10.3109/10409238.2015.1091804
7 Hewett, J., Gonzalez-Agosti, C., Slater, D., Ziefer, P., Li, S., Bergeron, D. et al. (2000) Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. *Hum. Mol. Genet.* 9, 1403–1413 doi:10.1093/hmg/9.9.1403
8 Hewett, J., Ziefer, P., Bergeron, D., Naismith, T., Boston, H., Slater, D. et al. (2003) TorsinA in PC12 cells: localization in the endoplasmic reticulum and response to stress. *J. Neurosci. Res.* 72, 158–168 doi:10.1002/jnr.10567
9 Kustedo, K., Deechongkit, S., Kelly, J.W. and Cravatt, B.F. (2003) Recombinant expression, purification, and comparative characterization of torsinA and its torsion dystonia-associated variant ΔE-torsinA. *Biochemistry* 42, 15333–15341 doi:10.1021/bi0349569
10 Neuwald, A.F., Aravind, L., Spouge, J.L. and Koonin, E.V. (1999) AAA+: a class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes. *Genome Res.* 9, 27–43 PMID:9927482
11 Callan, A.C., Bunning, S., Jones, O.T., High, S. and Swanton, E. (2007) Biosynthesis of the dystonia-associated AAA+ ATPase torsinA at the endoplasmic reticulum. *Biochem. J.* 401, 607–612 doi:10.1042/BJ20061313
12 Zhao, C., Brown, R.S.H., Tang, C.-H.A., Hu, C.-C.A. and Schlieker, C. (2016) Site-specific proteolysis mobilizes TorsinA from the membrane of the endoplasmic reticulum (ER) in response to ER stress and B cell stimulation. *J. Biol. Chem.* 291, 9469–9481 doi:10.1074/jbc.M115.709337
13 Demircioglu, F.E., Sosa, B.A., Ingram, J., Poehg, H.L. and Schwartz, T.U. (2016) Structures of TorsinA and its disease-mutant complexed with an activator reveal the molecular basis for primary dystonia. *eLife* 5, e17983 doi:10.7554/eLife.17983
14 Kamm, C., Boston, H., Hewett, J., Wilbur, J., Corey, D.P., Hanson, P.I. et al. (2004) The early onset dystonia protein TorsinA interacts with kinesin light chain 1. *J. Biol. Chem.* 279, 18988–18992 doi:10.1074/jbc.M401332200
15 Grillit, M., Dominguez Gonzalez, B., Sicart, A., Pöttler, M., Cascalho, A., Billon, K. et al. (2016) Torsins are essential regulators of cellular lipid metabolism. *Dev. Cell* 38, 235–247 doi:10.1016/j.devcel.2016.06.017
16 Ozelius, L.J., Page, C.E., Klein, C., Hewett, J.W., Mineta, M., Leung, J. et al. (1999) The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. *Genomics* 62, 377–384 doi:10.1016/S0888-7543(99)00639-3
17 McLean, P.J., Kawamata, H., Shariff, S., Hewett, J., Sharma, N., Ueda, K. et al. (2002) Torsina and heat shock proteins act as molecular chaperones: suppression of α-synuclein aggregation. *J. Neurochem.* 83, 846–854 doi:10.1046/j.1471-4159.2002.01190.x
18 Caldwell, G.A., Cao, S., Sexton, E.G., Gelwix, C.C., Bevel, J.P. and Caldwell, K.A. (2003) Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins. *Hum. Mol. Genet.* 12, 307–319 doi:10.1093/hmg/ddg027
19 Kuner, R., Teisemann, P., Trutzel, A., Naim, J., Richter, A., Schmidt, N. et al. (2003) Torsina protects against oxidative stress in COS-1 and PC12 cells. *Neurosci. Lett.* 350, 153–156 doi:10.1016/S0304-3940(03)00904-2
20 Shaikhidinov, P., Sandu, D., Potla, U., Armata, I.A., Walker, R.H., McNaught, K.S. et al. (2005) Transgenic mouse model of early-onset DYT1 dystonia. *Hum. Mol. Genet.* 14, 125–133 doi:10.1093/hmg/ddi012
Saccharomyces cerevisiae

Parsell, D.A., Kowal, A.S. and Lindquist, S. (1994) Prion propagation and the neurological disease early-onset torsional dystonia. J. Biol. Chem. 269, 12727–12747 doi:10.1074/jbc.269.21.12727

Sweeny, E.A. and Shorter, J. (2016) Mechanistic and structural insights into the prion-disaggregase activity of Hsp104. Proc. Natl Acad. Sci. U.S.A. 113, 2011–2016 doi:10.1073/pnas.1601291113

Lum, R., Tkach, J.M., Vierling, E. and Glover, J.R. (2004) Evidence for an unfolding/threading mechanism for protein disaggregation by Hsp104. J. Mol. Biol. 343, 280–296 doi:10.1016/j.jmb.2004.04.051

DeSantis, M.E. and Shorter, J. (2012) The elusive middle domain of Hsp104 and ClpB: location and function. J. Biol. Chem. 287, 23331–23338 doi:10.1074/jbc.M112.363059

Wendler, P., Shorter, J., Snead, D., Plisson, C., Clare, D.K., Lindquist, S. et al. (2009) Motor mechanism for protein threading through Hsp104. EMBO J. 28, 1040–1050 doi:10.1038/emboj.2008.477

von der Haar, T., Jossé, L., Wright, P., Zenthon, J. and Tuite, M.F. (2007) Development of a novel yeast cell-based system for studying the aggregation of Alzheimer’s disease-associated Aβ peptides in vivo. Neurobiol. Dis. 30, 136–147 doi:10.1016/j.nbd.2007.01.021

Bastow, E.L., Peswani, A.R., Tarrant, D.S.J., Pentland, D.R., Chen, X., Morgan, A. et al. (2016) New links between SOD1 and metabolic dysfunction of Alzheimer’s disease. Methods Mol. Biol. 1355, 263–279 doi:10.1007/978-1-4939-2841-8_20

Zacchi, L.F., Wu, H.-C., Bell, S.L., Millen, L., Paton, A.W., Paton, J.C. et al. (2014) The bip molecular chaperone plays multiple roles during the differentiation of Caenorhabditis elegans. Cell Stress Chaper. 19, 617–631 doi:10.1007/s12192-014-0173-2

Jung, G. and Masison, D.C. (2001) Guanidine hydrochloride inhibits Hsp104 activity. FEBS Lett. 499, 219–222 doi:10.1016/S0014-5793(01)02644-3

Kummer, E., Oguchi, Y., Seyffer, F., Buka, B. and Mogk, A. (2013) Mechanism of Hsp104/CtpB inhibition by prion curing guanidinium hydrochloride. FEBS Lett. 587, 810–817 doi:10.1016/j.febslet.2013.02.011

Hanson, P.J. and Whiteheart, S.W. (2005) AAA+ proteins: have engine, will work. Nat. Rev. Mol. Cell Biol. 6, 519–529 doi:10.1038/nrm1684
References

86 Frederick, K.K., Debelouchina, G.T., Kayatekin, C., Dorminy, T., Jacavone, A.C., Griffin, R.G. et al. (2014) Distinct prion strains are defined by amyloid core structure and chaperone binding site dynamics. *Chem. Biol.* **21**, 295–305 doi:10.1016/j.chembiol.2013.12.013

87 Rose, A.E., Zhao, C., Turner, E.M., Stoyer, A.M. and Schlieker, C. (2014) Arresting a Torsin ATPase reshapes the endoplasmic reticulum. *J. Biol. Chem.* **289**, 552–564 doi:10.1074/jbc.M113.515791

88 Brown, R.S.H., Zhao, C., Chase, A.R., Wang, J. and Schlieker, C. (2014) The mechanism of Torsin ATPase activation. *Proc. Natl Acad. Sci. U.S.A.* **111**, E4822–E4831 doi:10.1073/pnas.1415271111

89 Sosa, B.A., Demircioglu, F.E., Chen, J.Z., Ingram, J., Ploegh, H.L. and Schwartz, T.U. (2014) How lamina-associated polypeptide 1 (LAP1) activates Torsin. *eLife* **3**, e03239 doi:10.7554/elife.03239

90 Hainzl, O., Wegèle, H., Richter, K. and Buchner, J. (2004) Cns1 is an activator of the Ssa1 ATPase activity. *J. Biol. Chem.* **279**, 23267–23273 doi:10.1074/jbc.M402189200